|
Thanks to SoCalBio Weekly Update Sponsor
|
| Meet New SoCalBio Member Companies | |
|
Join SoCalBio
Join SoCalBio leaders to promote the biotech and device industries in Los Angeles, Orange County and neighboring communities for job creation and overall economic growth.
|  |
Recommended Events
January 23 - 24, 2012
Computer History Museum, Silicon Valley
********************
|
| Thanks to SoCalBio Media Partners
|
|
|
January 9, 2012 
|  Editor: Ahmed Enany
President & CEO
Southern California
Biomedical Council
enany@socalbio.org
www.socalbio.org
|
SoCalBio Events
| 
Eric Golden, President of Equipois, Speaks About the Promise of Exoskeletal Devices at the SoCalbio Networking Forum
Tuesday, January 24, 2012
4:00 to 7:00 PM UCLA Faculty Center |
Founded in 2006, Equipois is a West Los Angeles-based company affiliated with Nant Holdings, a Patrick Soon-Shiong company. Equipois designs and manufactures revolutionary dynamic exoskeletal technologies that support the musculoskeletal system while allowing full spatial and rotational freedom of motion. The company's patented zeroG and X--Ar systems are designed to support a range of manufacturing, heavy industrial, bioresearch, medical, defense and other applications in order to increase productivity and safety... More information
|
| Do You Know? | |
Companies utilizing the SoCalBio Group Purchasing Program enjoy significant savings on products and services procured through this program. Here are the actual savings generated from the SoCalBio-FedEx program for shipping services:
|
Shipping Services Spend Range Under the SoCalBio - FedEx Program
| Average Savings Under the SoCalBio - FedEx Program | | > $100k | $39,302 | | $50k - $100k | $16,336 | | $25k - $50k | $12,895 | | $10k - $25k | $5,062 | | $1k - $10k | $1,168 | | < $1000 | $129 |
The savings represent average annual savings of the actual program participants in the SoCalBio-FedEx program. Results will vary based on individual company's Product Mix and Purchase Volume ... Learn more
|
| New SoCalBio Board Member | Diane Palumbo of MannKind Corp Elected to SoCalBio Board of Directors
 On December 14, members of the SoCalBio Board of Directors unanimously elected Ms Palumbo to the SoCalBio Board. Currently, Ms. Palumbo serves as Corporate Vice President of Human Resources at MannKind Corp. in Valencia. She also chairs the SoCalBio Women, Work and Wisdon (W3) group which seeks to support and nurture women-led bioscience companies in Southern California. Prior to MannKind, Ms. Palumbo held various positions with Amgen, Inc., including Senior Director, Human Resources. In addition, Ms. Palumbo has held Human Resources positions with Unisys and Mitsui Bank Ltd. of Tokyo. She holds a master's degree in Business Administration from St. John's University, New York and a bachelor's degree, magna cum laude, also from St. John's University. |
Research Grants
| | DoD Announces Congressionally-Mandated Medical Research Grant Funding for 2012 |
The Fiscal Year 2012 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense (DoD) office of Congressionally Directed Medical Research Programs (CDMRP):
- Amyotrophic Lateral Sclerosis Research Program - $6.4 million
- Autism Research Program - $5.1 million
- Bone Marrow Failure Research Program - $3.2 million
- Breast Cancer Research Program - $120 million
- Duchenne Muscular Dystrophy Research Program - $3.2 million
- Gulf War Illness Research Program - $10 million
- Lung Cancer Research Program - $10.2 million
..... Click here to read full press release
|
Drug Approval
| | Drug Approvals Hit a Seven-Year High in 2011 on Improved Data |
 The Food and Drug Administration cleared 30 new treatments in 2011 compared with 21 the year before, a Bloomberg review of agency records shows. Johnson & Johnson and GlaxoSmithkline each had three products approved after no company had more than one medicine cleared in 2010 ... Read more
|
| RNAi Partnership | | Alnylam and ArrowHead form collaboration and licensing agreement |
Alnylam has granted Arrowhead a license under its intellectual property that enables the discovery, development, and commercialization of an RNAi therapeutic targeting the hepatitis B virus. Alnylam is eligible to receive from Arrowhead milestone payments and royalties on sales of product resulting from the license. In addition, Alnylam has received a license from Arrowhead to utilize their Dynamic Polyconjugate delivery technology for an RNAi therapeutic product ... Read more |
| Patenting | ISTA Pharmaceuticals Announces U.S. Patent Allowance for PROLENSA
PROLENSA (bromfenac ophthalmic solution) is being developed as a once-daily topical nonsteroidal anti-inflammatory compound for the treatment of ocular inflammation and pain following cataract surgery .. Read more |
| Obesity | Arrowhead Commences Obesity Clinical Trial
The Pasadena-base Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound. AdipotideTM specifically targets and kills blood vessels supplying white fat tissue. The Phase I clinical trial will be conducted by The University of Texas MD Anderson Cancer Center, which will bear the costs of the planned clinical trial ... Read more |
| M&As | Valeant Says No Agreement Reached on $327 Million Hostile Offer for Ista
Valeant Pharmaceuticals International Inc., Canada's biggest drugmaker, said no agreement has been reached on its hostile $327 million offer for Ista (ISTA) Pharmaceuticals Inc. There have been a number of talks with Ista over the $6.50- a-share bid, Mississauga, Ontario-based Valeant said in a regulatory filing today. No agreement has been reached on a price or process, the company said. Valeant said today that there's a deadline of Jan. 31 on the offer because it is "unwilling to spend too much time," according to the filing... Read more |
Jobs Available
| |
Quest Diagnostics
Quest currently has the following openings in its labs located in the Greater Los Angeles region. To get more information and to apply, contact Marisa Stubbs, Sr. Staffing Specialist - CLS recruiting for Southern California at Quest Diagnostics, at marisastubbs16@gmail.com:
Valencia-Nichols Institute/Specialty Labs
- CLS I in AL
- Specimen Tech I
Valencia-Clinical Trials division
- Histotechnologist I and II
- Sr. Scientist, Anatomic Pathology
- CLS I in Immunology
- CLS III/Lead in Immunoflow
- Sr. Scientist, Test Development
- Project Manager
- Mgr, QA Technical
West Hills Lab
- CLS I Immunochemistry, Microbiology, Molecular
- Supervisor, Lab CLS AutoChem
- Lab Assistant
- Asst. Specimen Processor
- QA
- Black Belt
- Director of Pathology
- Pathology Assistant
- Grossing Technician
- Histotechnologist I & II
Cypress-Focus Diagnostics
- Laboratory Technician II Molecular Diagnostics
- Laboratory Technician I & II Clinical Trials
San Juan Capistrano-Nichols Institute
- CLS I & II Biochemical Genetics
- CLS I Hematology/Oncology, Microbiology, Molecular, Steroids, Virology
- Lab Associates
- Histotechnologist II
- Lab Supervisor, Hematology
Aviir, Inc. (Irvine)
Advanced Bionics (Sylmar & Valencia)
- Click here to see a list of 37 available engineering, manufacturing, clinical, quality and sales jobs at Advanced Bionics
Equipois (Los Angeles)
Neumedicines (Pasadena)
Chromologic (Pasadena)
|
|
| About SoCalBio |
 SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
|
|
